This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Altria (MO) Benefits From Low-Risk Products & Pricing Power
by Zacks Equity Research
Altria (MO) gains from expansion of IQOS and oral tobacco offerings such as on! Moreover, pricing power is aiding revenues.
Altria (MO) Poised on Solid Pricing, Growth in Low Risk Products
by Zacks Equity Research
Altria (MO) gains from rising popularity of IQOS and oral tobacco offerings. Moreover, pricing power is supporting revenue growth.
Phillip Morris (PM) Poised for Growth on RRPs & Strong Pricing
by Zacks Equity Research
Philip Morris' (PM) strong offerings in the reduced risk products space and solid pricing of combustible products are driving growth.
Altria (MO) Gains on Low Risk Tobacco Products & Strong Pricing
by Zacks Equity Research
Altria's (MO) efforts to boost oral tobacco offerings and expansion of IQOS across stores are yielding. Moreover, pricing power is aiding revenue growth.
Will RRPs Growth Keep Driving Philip Morris (PM) in 2021?
by Zacks Equity Research
Philip Morris (PM) is gaining from growing popularity of IQOS, which is boosting revenues in the RRPs category.
Altria (MO) Gains on Low-Risk Products Amid Soft Cigarette Sales
by Zacks Equity Research
Altria (MO) is gaining from the popularity of low-risk tobacco alternatives such as IQOS and on!, as well as prudent pricing strategies.
Philip Morris's (PM) IQOS 3 Receives FDA Authorization for Sale
by Zacks Equity Research
FDA approves the sale of Philip Morris's (PM) IQOS devices in the United States. The latest device includes a number of technological advancements compared with its predecessors.
Should Value Investors Choose British American (BTI) Stock?
by Zacks Equity Research
Is British American Tobacco (BTI) a great pick from the value investor's perspective right now? Read on to know more.
Oral Tobacco Unit Supports Altria Amid Poor Cigarette Sales
by Zacks Equity Research
Altria (MO) is gaining from rising popularity of low risk tobacco alternatives. However the company's smokeable unit is bearing the brunt of soft cigarette sales.
RRPs a Respite for Philip Morris Amid Low Cigarette Sales
by Zacks Equity Research
Philip Morris (PM) is gaining from growing popularity of IQOS. However, low cigarette sales is a dampener.
BTI or MO: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BTI vs. MO: Which Stock Is the Better Value Option?
Is British American Tobacco (BTI) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is British American Tobacco (BTI) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
BTI vs. MO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
BTI vs. MO: Which Stock Is the Better Value Option?
Should Value Investors Pick British American Tobacco (BTI)?
by Zacks Equity Research
Let's see if British American Tobacco (BTI) stock is a good choice for value-oriented investors right now from multiple angles.
Zacks.com featured highlights include: Bristol-Myers Squibb, Urban Outfitters, Hewlett Packard, Cardinal Health and British American Tobacco
by Zacks Equity Research
Zacks.com featured highlights include: Bristol-Myers Squibb, Urban Outfitters, Hewlett Packard, Cardinal Health and British American Tobacco
5 Excellent GARP Stocks With Discounted PEG
by Urmimala Biswas
PEG-based investing becomes more rewarding when other relevant parameters are considered.
Has British American Tobacco p.l.c. (BTI) Outpaced Other Consumer Staples Stocks This Year?
by Zacks Equity Research
Is (BTI) Outperforming Other Consumer Staples Stocks This Year?
Should Value Investors Buy British American Tobacco (BTI) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Philip Morris Trims View on Berlin Plant Closure Charges
by Zacks Equity Research
Charges of almost $355 million related to the closure of Berlin plant compel Philip Morris (PM) to trim 2019 earnings view. It now expects earnings of $4.53.
Will Pricing be an Upside for Altria (MO) in Q3 Earnings?
by Zacks Equity Research
Gains from pricing and savings efforts are likely to be reflected on Altria's (MO) Q3 results. However, receding cigarette sales volumes are a concern.
Will Cigarette Woes Hurt Philip Morris (PM) in Q3 Earnings?
by Zacks Equity Research
Philip Morris' (PM) Q3 performance to gain from pricing and IQOS expansion. However, low cigarette sales volumes are a worry.
Can Altria Battle Dwindling Cigarette Sales & Vaping Worries?
by Zacks Equity Research
Altria (MO) is reeling under regulatory pressures in the tobacco industry. However, higher pricing is likely to provide support.
Philip Morris (PM) Hikes Dividend to Boost Shareholders Value
by Zacks Equity Research
Philip Morris (PM) is consistently boosting shareholders' value via dividend payouts. The company announces dividend hike of 2.6%.
Trump May Ban Flavored E-Cigarettes: Who Wins, Who Loses
by Zacks Equity Research
Vaping is a growing trend among youngsters, but Trump's recent threat to ban flavored e-cigarettes raises questions. Will traditional cigarette get back its lost glory?